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Abstract
Oncogenic somatic chromosomal rearrangements involving the NTRK1, NTRK2 or NTRK3 genes (NTRK gene fusions) occur in
up to 1% of all solid tumors, and have been reported across a wide range of tumor types. The fusion proteins encoded by such
rearranged sequences have constitutively activated TRK tyrosine kinase domains, providing novel therapeutic anticancer targets.
The potential clinical effectiveness of TRK inhibition in patients with tumors harboring NTRK gene fusions is being assessed in
phase I and II trials of TRK inhibitors, such as larotrectinib and entrectinib. Clinical trial results have demonstrated that
larotrectinib is generally well tolerated and has shown high response rates that are durable across tumor types. These data validate
NTRK gene fusions as actionable genomic alterations. In this review, we present the clinical data, discuss the different approaches
that might be used to routinely screen tumors to indicate the presence of NTRK gene fusions, explore the issue of acquired
resistance to TRK inhibition, and reflect on the wider regulatory considerations for tumor site agnostic TRK inhibitor drug
development.
1 Introduction
The neurotrophic tyrosine kinase receptors, TRKA, TRKB
and TRKC, are single-pass transmembrane proteins that
function as high affinity receptors for neurotrophins, a family
of proteins that regulate many aspects of neuronal develop-
ment and function [1]. TRKA, TRKB and TRKC receptors
are encoded by theNTRK1,NTRK2, andNTRK3 genes, which
are located on human chromosomes 1q23.1, 9q21.33, and
15q25.3, respectively. The first member of this gene family
to be characterized was the NTRK1 gene, which was initially
identified in a human colon carcinoma as the 3′ component of
a somatic gene fusion between the non-muscle tropomyosin
gene and a gene encoding a previously unknown protein ty-
rosine kinase [2]. The closely related human NTRK2 and
NTRK3 genes were subsequently identified and mapped, with
the encoded TRK proteins showing 40% amino acid identity
overall, conserved cysteine residues in the extracellular do-
mains and conserved tyrosine residues in the intracellular do-
main [3–5]. The overall structure of the three TRK proteins is
also conserved, with the extracellular domains of each having
a cysteine-rich cluster, three leucine-rich repeats, another
cysteine-rich cluster and two immunoglobulin-like domains,
followed by a transmembrane domain and an intracellular
tyrosine kinase [1].
In normal signaling processes, neurotrophin ligand binding
to the TRK extracellular domain leads to receptor dimeriza-
tion and autophosphorylation of specific tyrosine residues in
the intracellular kinase domain, leading to elevated tyrosine
kinase activity. Through the binding of various adaptor pro-
teins, activated TRK receptors engage diverse signaling path-
ways (Fig. 1), including those downstream of RAS,
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phosphatidylinositol 4,5-bisphosphate 3-kinase and, phospho-
lipase C-ɣ1, modifying such functions as neuronal differenti-
ation, including neurite outgrowth, cell survival, cell growth,
and synaptic plasticity [1, 6].
Following the initial observation in colon cancer, it is now
apparent that somatic fusions involving the NTRK1, NTRK2
or NTRK3 genes (NTRK gene fusions) can occur in a wide
range of human tumor types [6, 7]. While, such fusions in
common human cancers may occur at relatively low frequen-
cy [8–10], in certain rare tumors, NTRK gene fusions are
highly characteristic, and may be present in most cases [11,
12]. Typically, in such somatic chromosomal rearrangements,
the 5′ region of a gene that is expressed by the tumor cell
progenitor is joined with the 3′ region of one of the NTRK
genes. The resultant mRNA fusion transcript encodes an in-
frame protein comprising the N-terminus of the fusion partner
joined to the C-terminus of the TRK protein, including the
tyrosine kinase domain. In the majority of characterized fu-
sions, the 5′ partner gene sequence encodes one or more iden-
tifiable dimerization domains, which would be predicted to
lead to constitutive activation of the TRK tyrosine kinase do-
main [6]. In addition to gene fusion events, somatic point
mutations of NTRK genes have also been identified in human
tumors, [13, 14]. Whether such mutations might be of pre-
dictive significance in relation to TRK inhibitor therapy is
not definitively known. The lack of response in patients
with NTRK point mutations in a larotrectinib phase I trial
and an in silico analysis of these events suggest that
NTRK point mutations may not be useful biomarkers in
this context [15, 16].
There are several examples of chromosomal rearrange-
ments in tumor cells resulting in gene fusions between an
expressed 5′ partner and a 3′ partner encoding a tyrosine ki-
nase that have been exploited therapeutically. Tyrosine kinase
genes involved in such somatic fusions include ABL, ALK,
ROS1 and RET [17, 18]. Small molecule inhibitors of these
tyrosine kinases have been developed and have been shown
clinically to be highly effective anticancer agents in patients
with fusion-positive tumors. The efficacy of these tyrosine
kinase inhibitors (TKIs) confirms that such gene fusions
may function as tumor drivers, which, when targeted, lead to
a reduction in the viability of the tumor cells, manifested as a
clinical response. Such data suggested that the development of
TKIs targeting TRK might be a novel and effective therapeu-
tic approach for the treatment of patients with tumors harbor-
ing NTRK gene fusions. There are number of such agents at
various stages of clinical development, some of which target
multiple kinases, and one of which, larotrectinib, is highly
specific for TRK kinases (Table 1). As most of the published
data relating to the clinical efficacy of TRK inhibitors in
patients with TRK fusion cancer have so far been derived
from patients included in phase I and II trials of
larotrectinib and phase I trials of the multikinase inhibitor
entrectinib, our review will focus predominantly on these
agents to illustrate the potential of this emerging class of
drugs.
Larotrectinib is a highly selective, orally administered,
ATP-competitive inhibitor of TRKA, TRKB and TRKC, with
IC50 values in the range of 5.3–11.5 nM in cellular assays and
minimal off-target activity against other kinases [7]. In addi-
tion, in vitro studies have shown that cell lines harboring
NTRK gene fusions are sensitive to larotrectinib, with IC50
values again in the low nanomolar range. Entrectinib is an
orally administered small molecule inhibitor of TRKA,
Fig. 1 NTRK gene fusions. LBD ligand binding domain, TM transmembrane, TK tyrosine kinase
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TRKB, TRKC, ROS1, ALK, JAK2, and ACK1 kinases, with
IC50 values for the TRK kinases in the low nanomolar range
[19]. Entrectinib has shown antiproliferative and antitumor
activity in in vitro and in vivo models of TRK fusion cancer
[20]. Such data provide a strong scientific rationale for clinical
studies of these two agents in patients with solid tumors har-
boring NTRK gene fusions.
2 NTRK Gene Fusions
It has been estimated thatNTRK gene fusions may occur in up
to 1% of all solid tumors and may involve a range of different
5′ partners [6, 7]. A particularly high frequency of such events
has been identified in certain rare pediatric and adult tumor
types. While fusions may occur in any of the three NTRK
genes, it appears to be the case that, with the possible excep-
tion of brain tumors, they more commonly arise in the NTRK1
andNTRK3 genes, withNTRK2 less frequently involved [6, 7,
9]. Depending on the tumor type, the 5′ partner and NTRK
gene partner may be characteristic or may be variable [6].
Over 60 different 5′ partner genes have so far been reported
in human TRK fusion tumors (Table 2), with the NTRK1 gene
having the most fusion partners identified to date.
Pediatric tumor types in which NTRK gene fusions oc-
cur at high frequency include infantile fibrosarcoma, the
most commonly occurring non-rhabdomyosarcoma soft
tissue sarcoma in children under 1 year of age. It has been
reported that the majority of such tumors harbor an ETV6-
NTRK3 fusion [11, 50], although cases with EML4-NTRK3
fusions have been identified [49]. In addition, an LMNA-
NTRK1 fusion in a congenital infantile fibrosarcoma, [62]
and LMNA-NTRK1 and TMP3-NTRK1 fusions in ETV6-
NTRK3 fusion-negative congenital/infantile soft tissue le-
sions with similar morphological features to congenital in-
fantile fibrosarcoma have been identified [63]. Similarly,
most cases of the cellular subtype of the rare pediatric renal
tumor, congenital mesoblastic nephroma, have ETV6-
NTRK3 fusions [51, 52], although again, the EML4-
NTRK3 fusion may also be found [49]. The identification
of variant NTRK gene fusions in these particular tumor types
is of significance in relation to the screening strategies that
might be used in these indications to select patients for TRK
inhibitor therapy. NTRK gene fusions have also been identi-
fied in other pediatric tumor types at moderately high frequen-
cies, including non-rhabdomyosarcoma soft tissue sarcoma
[64], childhood high grade glioma [43], pediatric papillary
thyroid cancer [65, 66], and spitzoid neoplasms [32]. Rare
cancers that may occur in both adults and children which have
a high frequency of NTRK gene fusions include mammary
analogue secretory carcinoma of the salivary gland and secre-
tory carcinoma of the breast. In both tumor types, it has been
reported that more than 90% of cases harbor an ETV6-NTRK3
fusion [12, 53].
Table 1 Active clinical trials of TRK inhibitors in patients with NTRK fusion tumors
Agent Kinase targets Phase NTRK fusion tumor type Start date Status Estimated
participants
Larotrectinib TRKA, TRKB, TRKC I Advanced solid tumors May 2014 Recruiting 90
II Advanced solid tumors October 2015 Recruiting 151
I/II Advanced solid or primary CNS tumors
(pediatric)
December 2015 Recruiting 92
Entrectinib TRKA, TRKB, TRKC,
ALK, ROS1
I Locally advanced or metastatic solid tumorsa June 2014 Recruiting 125
II Locally advanced or metastatic solid tumorsa October 2015 Recruiting 300
I/Ib Recurrent or refractory solid tumors and
primary CNS tumors (pediatric)
December 2015 Recruiting 190
DS-6051b TRKA, TRKB, TRKC, ROS1 I Advanced solid tumorsb September 2014 Not recruiting 70
I Advanced solid tumors (Japanese patients) February 2016 Not recruiting 15
TSR-011 TRKA, TRKB, TRKC, ALK I/IIa Advanced solid tumors and lymphomasc October 2012 Unknown 72
TPX-0005d TRKA, TRKB, TRKC, ALK,
ROS1
I/II Locally advanced or metastatic solid tumor
(including non-Hodgkin lymphoma)a
February, 2017 Recruiting 450
LOXO-195d TRKA, TRKB, TRKC I/II Advanced solid tumor progressing after prior
TRK inhibitor treatment
July, 2017 Recruiting 93
As registered with ClinicalTrials.gov
CNS central nervous system
a Inclusion of patients with ROS1, or ALK gene rearrangements permitted
b Inclusion of patients with ROS1 gene rearrangements permitted
c Inclusion of patients with ALK gene rearrangements permitted
d Second generation TRK inhibitor with activity against TRK proteins with resistance mutations
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Table 2 NTRK gene fusions identified in human tumors
NTRK gene Fusion partner and chromosomal
localization
Tumor type Citations
NTRK1 (1q23.1) ARHGEF2 1q22 Glioblastoma [21]
BCAN 1q23.1 Glioblastoma; glioneuronal tumor, pilocytic astrocytoma [22–24]
CEL 9q34.13 Pancreatic cancer [25]
CD74 5q33.1 Lung cancer [10]
CHTOP 1q21.3 Glioblastoma [21]
CGN 1q21.3 Breast cancer [26]
COP1 1q25.1–q25.2 Large cell neuroendocrine cancer [27]
CTRC 1p36.21 Pancreatic cancer [7]
DDR2 1q23.3 Melanoma [28]
GATAD2B 1q21.3 Breast cancer [26]
GON4L 1q22 Melanoma [7, 28]
GRIPAP1 Xp11.23 Lung cancer [29]
IRF2BP2 1q42.3 Lung cancer; thyroid cancer [7, 9, 30, 31]
LMNA 1q22 Appendiceal cancer; breast cancer; cholangiocarcinoma;
colorectal cancer; soft tissue sarcoma; Spitzoid
neoplasm; uterine sarcoma
[7, 23, 26, 30, 32–34]
LRRC71 1q23.1 Uterine endometrial cancer [29]
MDM4 1q32.1 Breast cancer [26]
MIR548F1 10q21.1 Pediatric mesenchymal tumor [35]
MPRIP 17p11.2 Lung cancer [10, 36]
MRPL24 1q23.1 Lung cancer [37]
NFASC 1q32.1 Glioblastoma [9, 22]
P2RY8 Xp22.33 and Yp11.3 Lung cancer [30]
PDE4DIP 1q21.2 Soft tissue sarcoma [7]
PEAR1 1q23.1 Breast cancer [26]
PLEKHA6 1q32.1 Colon cancer [7]
PPL 16p13.3 Thyroid carcinoma [7, 21]
RABGAP1L 1q25.1 Intrahepatic cholangiocarcinoma [38]
SCYL3 1q24.2 Colorectal cancer [39]
SSBP2 5q14.1 Thyroid cancer [9]
SQSTM1 5q35.3 Infantile fibrosarcoma; lung cancer; thyroid cancer [7, 9, 40, 41]
TFG 3q12.2 Thyroid cancer [9, 42]
TP53 17p13.1 Spitzoid neoplasm [32]
TPM3 1q21.3 Breast cancer; cholangiocarcinoma; colorectal cancer;
glioma; infantile fibrosarcoma; lung cancer; soft
tissue sarcoma; thyroid cancer; uterine sarcoma
[7, 9, 21, 26, 30, 34, 43–45]
TPR 1q31.1 Lung cancer; papillary thyroid cancer; uterine sarcoma;
pediatric mesenchymal tumor
[7, 34, 35, 42]
TRIM63 1p36.11 Melanoma [7, 28, 30]
NTRK2 (9q21.33) AFAP1 4p16.1 Glioma [9]
AGBL4 1p33 Glioma [43]
BCR 22q11.23 Glioblastoma [30]
DAB2IP 9q33.2 Colorectal cancer [37]
GKAP1 9q21.32 Glioblastoma [24]
KCTD8 4p13 Glioblastoma [24]
NACC2 9q34.3 Astrocytoma [46]
NOS1AP 1q23.3 Anaplastic astrocytoma [24]
PAN3 13q12.2 Squamous cell cancer of the head and neck [9]
QKI 6q26 Astrocytoma [46, 47]
SQSTM1 5q35.3 Glioma [9]
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3 Efficacy and Safety of TRK Inhibitor Therapy
The efficacy of both larotrectinib and entrectinib in the treat-
ment of patients with TRK fusion cancer was initially reported
in multiple published case studies [33, 40, 54, 67–70]. The
safety and antitumor activity of larotrectinib have been further
explored in an integrated analysis of treatment outcomes in the
first 55 patients with tumors harboring NTRK gene fusions
consecutively enrolled into one of three clinical studies: a
phase I study in adults, a phase I/II study in children, and a
phase II study in adolescents and adults [7]. The primary end-
point for this combined analysis was the overall response rate,
as assessed by an independent radiology review committee.
Patients were aged from 4 months to 76 years and 17 different
tumor types were represented. The overall response rate ac-
cording to independent review was 75% (95%CI 61–85) with
71% of the responses ongoing at 1 year (Fig. 2). Responses
appeared to be independent of the age of the patient, the tumor
type and the particular gene fusion event. Larotrectinib was
generally well tolerated, with most adverse events being of
grade 1 or 2. The most common grade 3 or higher adverse
events were anemia (11% of patients), increased alanine ami-
notransferase or aspartate aminotransferase levels (7%), in-
creased body weight (7%), and decreased neutrophil count
(7%). Clinically significant treatment-related adverse events
were uncommon. In particular, there were no grade 4 or 5
treatment-related adverse events and no such grade 3 events
that occurred in more than 5% of patients. In the small number
of patients who had adverse events leading to dose reductions,
best responses were maintained at the lower doses. In addi-
tion, no patients discontinued treatment due to drug-related
adverse events. These data suggest that the long-term admin-
istration of larotrectinib will be feasible.
The integrated analysis included patients from the phase I
component of a first-in-child phase I/II study which enrolled
infants, children, and adolescents, aged 1 month to 21 years,
with a locally advanced or metastatic solid tumor or central
nervous system tumor [64]. This study began enrollment prior
Table 2 (continued)
NTRK gene Fusion partner and chromosomal
localization
Tumor type Citations
STRN 2p22.2 Soft tissue sarcoma [7]
TBC1D2 9q22.33 Glioblastoma [24]
TLE4 9q21.31 Ganglioglioma [48]
TRAF2 9q34.3 Melanoma [28, 30]
TRIM24 7q33-q34 Lung cancer [9]
VCL 10q22.2 Glioma [43]
VCAN 5q14.2-q14.3 Glioma [24]
NTRK3 (15q25.3) AFAP1 4p16.1 Glioblastoma [30]
AKAP13 15q25.3 Glioma [18]
BTBD1 15q25.2 Glioma [43]
EML4 2p21 Congenital mesoblastic nephroma; glioblastoma;
infantile fibrosarcoma; thyroid cancer
[30, 31, 49]
ETV6 12p13.2 Acute lymphoblastic leukemia; acute myeloid
leukemia; breast cancer; colorectal cancer;
congenital mesoblastic nephroma;
gastrointestinal stromal tumor; glioma; infantile
fibrosarcoma; lung cancer; mammary analog
secretory carcinoma of salivary gland;
melanoma; neuroendocrine cancer; secretory
breast cancer; soft tissue sarcoma; Spitzoid
neoplasm; thyroid cancer
[7, 11, 12, 23, 26, 30, 43, 50–59]
LYN 8q12.1 Squamous cell cancer of the head and neck [9]
MYH9 22q12.3 Spitzoid neoplasm [55]
MYO5A 15q21.2 Spitzoid neoplasm [55, 60]
RBPMS 8p12 Thyroid cancer; uterine sarcoma; [9, 34]
SQSTM1 5q35.3 Thyroid cancer [31, 61]
TFG 3q12.2 Fibrous tumor [41]
TPM4 19p13.12-p13.11 Soft tissue sarcoma [7, 30]
ZNF710 15q26.1 Glioblastoma [30]
Gene nomenclature and chromosomal localizations are described according to the Human Genome Nomenclature Committee database
Inhibition of TRK fusion proteins 549
to completion of the adult phase I larotrectinib study. With
responses seen in 14 (93%) of 15 pediatric patients with
Response Evaluation Criteria in Solid Tumors [71]
(RECIST)-evaluable tumors harboring NTRK gene fusions,
the demonstration of a favorable safety profile including min-
imal larotrectinib-associated neurological toxicity, and no ev-
idence of an impact on patient quality of life, this accelerated
clinical development program facilitated the early demonstra-
tion of the activity and feasibility of larotrectinib in pediatric
as well as adult patients. It consequently serves as a paradigm
to demonstrate how delays in pediatric anticancer drug devel-
opment can be minimized [72].
Preliminary data on the safety and efficacy of entrectinib
have also been reported from a combined analysis of two
phase I studies, ALKA-372-001 and STARTRK-1 [23], which
included four patients with tumors harboring NTRK gene fu-
sions. A thorough analysis of the activity of entrectinib in
patients with TRK fusion cancer is limited by this small sam-
ple size and the lack of other published clinical data. Of these
four patients, three had partial responses to entrectinib treat-
ment and one experienced stable disease by RECIST, with
three-dimensional volumetric assessment nevertheless indi-
cating a 60% reduction in total tumor burden in this patient.
Entrectinib was generally well tolerated, with most treatment-
related adverse events in the overall combined population of
119 patients with advanced solid tumors being grade 1 or 2 in
severity, and reversible with dose modifications. The most
common treatment-related adverse events of any grade were
fatigue/asthenia (46% of patients), dysgeusia (42%), paresthe-
sias (29%), nausea (28%), and myalgias (23%), with the most
common at grade 3 or higher being fatigue/asthenia (4%) and
weight increase (2%).
4 Clinical Detection of NTRK Gene Fusions
Consistent with the strong scientific rationale, the clinical data
available to date suggest that larotrectinib is a highly effective
antitumor agent in patients with tumors harboring NTRK gene
fusions [7, 64]. While it is possible that certain patients whose
tumors do not have such lesions might also benefit from TRK
inhibition, currently available data suggest that the develop-
ment of an effective diagnostic strategy to detect NTRK gene
fusions in tumor samples, and thereby to guide the selection of
TRK inhibitor treatment, will be optimal. There are currently
several approaches that may be used to directly detect or in-
directly imply the presence of gene fusion events in clinical
a b
c d
Fig. 2 Responses to larotrectinib
in clinical trials. a (baseline) and b
(after three cycles of larotrectinib)
are scans of a 2-year-old female
patient with a previously treated,
non-resectable infantile fibrosar-
coma harboring an ETV6-NTRK3
fusion. The patient was referred
for surgery after four cycles of
larotrectinib and a pathological
complete response with clear
margins was confirmed. c
(baseline) and d (after four cycles
of larotrectinib) are scans of a 45-
year-old female with a metastatic
lung adenocarcinoma harboring
an SQSTM1-NTRK1 fusion, and
pulmonary hypertrophic
osteoarthropathy. The patient had
evidence of disease progression
following treatment with multiple
cycles of platinum and
pemetrexed. After starting on
larotrectinib 100 mg BID, a dura-
ble partial response was achieved
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samples, including fluorescence in situ hybridization (FISH),
immunohistochemistry, reverse-transcriptase polymerase
chain reaction (RT-PCR) and next-generation sequencing
(NGS) of DNA or RNA (cDNA). Each of these approaches
has strengths and weaknesses. In selecting the most appropri-
ate diagnostic strategy, it must also be borne in mind that
certain rare tumors will have a very high incidence of NTRK
gene fusion events, while for other common tumor types such
as colorectal or lung cancers, the incidence may be around 1%
of cases. It is therefore possible that different diagnostic strat-
egies may be utilized for these different situations.
Break apart FISH has traditionally been viewed as a stan-
dard approach for the detection of clinically relevant gene
fusion events [73, 74], with RT-PCR providing additional
confirmation where 5′ and 3′ partners are non-variable [75].
For those tumor types where only one particular NTRK gene
fusion may be expected, for example, the ETV6-NTRK3 fu-
sion in secretory breast cancer, then a fusion FISH approach
with ETV6 and NTRK3 probes can be used with some degree
of confidence. However, given the variability of possible 5′
NTRK gene fusion partners in most tumor types, an approach
using break apart FISH probes for each of the three NTRK
genes (and therefore three separate FISH assays per patient
sample) would be required for comprehensive coverage.
One possible disadvantage of using break apart FISH is that
the 5′ gene fusion partner would not be identified. However,
this may not be an issue of particular importance, given that
there is to our knowledge currently no indication of a differ-
ential response to larotrectinib according to fusion partner. As
FISH assays are relatively costly, require considerable exper-
tise in interpretation, and may occasionally produce equivocal
hybridization results [39], their routine clinical use in this set-
ting may be restricted to those rare tumor types where partic-
ular NTRK gene fusions are essentially pathognomonic.
An alternative and/or complimentary approach to the de-
tection of NTRK gene fusion events might be provided by RT-
PCR, using primers cited in the coding sequence of the 5′
fusion partner and the NTRK kinase domain. However, the
large number of potential 5′ fusion partners in a screening
context would most likely make the development of compre-
hensive multiplex RT-PCR assays technically challenging. A
variation of this approach is to use multiplex RT-PCR reac-
tions to assess the ratio of 5′ and 3′ amplicons of each of the
NTRK genes, with an imbalance in this ratio for a particular
gene indicating a possible fusion event [76, 77]. The clinical
utility of this approach will rest on the validation of such
assays, which would in part be related to NTRK gene expres-
sion levels in NTRK gene fusion-negative cells.
The massively parallel sequencing capability facilitated by
NGS technology provides a new alternative approach to the
routine detection of gene fusions in clinical samples. NGS
methods may be based on the analysis of DNA or RNA, and
can be selectively targeted to analyze panels of genes of
particular interest or can cover the entire genome, exome or
transcriptome [78, 79].
Two general approaches exist to targeted panel design:
amplicon-based and hybrid capture-based methods. In
amplicon-based methods, PCR primers are designed to ampli-
fy a predetermined set of target sequences, and amplification
products are then sequenced by NGS. This approach is gener-
ally limited to smaller gene panels and is best utilized for the
detection of single nucleotide variants, small insertions and
deletions (indels) and known gene fusions. Amplicon-based
panels are typically used for the detection of cancer hotspot
point mutations in clinical samples. In capture-based methods,
biotin-labeled oligonucleotide probes targeting specific geno-
mic regions of interest (intronic regions where breakpoints are
known to occur are of particular importance for fusion detec-
tion) are hybridized with patient DNA. The probes are then
captured using streptavidin-coupled magnetic beads, and the
hybridized patient-derived sequences amplified by PCR and
sequenced byNGS. This design allows for the analysis of copy
number variation and the detection of novel fusion partners, as
long as one of the partners is known (e.g., an NTRK gene
fusion with any 5′ partner could theoretically be detected).
One advantage of using a broad-based NGS panel is that
multiple oncogenic genomic events can be identified from one
sample, thereby obviating the need for multiple tests and
aiding in sample conservation. However, one of the possible
drawbacks in using selective assays to detect NTRK gene fu-
sions is that, currently, available gene panels may not be con-
figured to permit the detection of all potential fusion events,
even if a hybrid capture design is used. For example, the US
Food and Drug Administrat ion (FDA) approved
FoundationOne CDx NGS in vitro diagnostic can detect only
selected fusions in DNA samples, which by design does not
include those involving NTRK3 [80], and has only partial
intron coverage for NTRK1 and NTRK2. Of particular note,
the large NTRK introns create inherent complexity and chal-
lenges for DNA-based NGS approaches. To use an alterna-
tive approach of whole genome sequencing would, how-
ever, add to the cost and complexity of analysis, would
necessitate a reduction in analytical sensitivity due to de-
creased sequencing depth, and would increase the time
required to generate results [79].
Though a circulating tumor (ct)DNA-based assay could
theoretically simplify biopsy procedures, these assays suffer
from the same inherent challenges as all tissue DNA-based
NGS approaches, which are compounded by the specific de-
tection issues inherent in all ctDNA assays. Additionally, as
recently noted in an American Society of Clinical Oncology
and College of American Pathologists joint review, although
certain ctDNA assays have demonstrated clinical validity and
utility in advanced cancer, there is currently insufficient evi-
dence of such for the majority of assays, which would include
those relating to gene fusions [81].
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The detection of gene fusions through RNA-based NGS
may provide an attractive alternative approach to DNA-
based NGS assays [82]. RNA-based NGS allows for assay
design without the need to cover the entirety ofNTRK intronic
regions. Additionally, when using such methods, gene fusions
which do not result in an expressed kinase will not be detect-
ed. However, the lower stability of RNA compared with DNA
poses challenges with regard to the collection of clinical sam-
ples for such diagnostic assessments. Nevertheless, in the fu-
ture, it is likely that NGS diagnostics which rely on RNA for
fusion detection will increasingly be used to facilitate the de-
tection of NTRK gene fusions in routine clinical practice.
In comparative studies, NGS has demonstrated superior
performance in terms of fusion detection relative to other ge-
nomic testing methods. Specifically, when samples scored
negative for particular fusions by FISH have been rescreened
using NGS, a considerable fraction have been found to harbor
those previously tested for fusion [83–85]. Factors that might
explain such discrepancies include the presence of complex
chromosomal rearrangements, technical issues with the FISH
process, and the higher sensitivity of NGS. One further factor
that should be considered is that, with the exception of the US,
patient access to tumor NGS in clinical diagnostic settings is
currently extremely limited, although this situation is likely to
change over coming years.
While approaches based on molecular analyses are gener-
ally seen as the most accurate methods for identifying samples
harboring gene fusion events, standard immunohistochemis-
try may still prove an extremely cost-effective and useful
screening approach in this context. This is evidenced by cur-
rent clinical guidelines relating to the selection of patients with
lung cancer for ALK TKI treatment, which draw an equiva-
lence between immunohistochemistry and FISH testing in the
identification of tumors harboring ALK gene fusions [86].
Although the evidence-based setting of appropriate thresholds
for scoring positivity in different tumor types might be neces-
sary for routine clinical use of an immunohistochemistry-
based assay for TRK fusion proteins, it might be that a less
rigorous scoring system could enable the use of a pan-TRK
immunohistochemistry assay for screening purposes, follow-
ed by reflex testing using a molecular method.
The feasibility of developing such an assay has been sug-
gested by two recent studies [30, 35]. The first of these com-
pared the performance of the pan-TRK monoclonal antibody
EPR17341 (Abcam) withMSK-IMPACT, a DNA-based NGS
assay and an Archer Dx fusion assay, an RNA-based NGS
assay. Of 23 tumors deemed to have NTRK gene fusions by
MSK-IMPACT, NTRK fusion transcripts were not detected in
two using the Archer Dx assay. Of the remaining 21 samples,
20 were found to be positive for TRK protein by pan-TRK
immunohistochemistry. Twenty additional tumors scored neg-
ative for NTRK gene fusion transcripts by Archer Dx analysis
were a l so scored nega t ive for TRK prote in by
immunohistochemistry, giving a sensitivity and specificity
for pan-TRK immunohistochemistry in relation to the detec-
tion of tumors with transcribed NTRK gene fusions of 95 and
100%, respectively, based on this specific set of samples. In
the second study, the same pan-TRK monoclonal antibody
was evaluated in pediatric mesenchymal tumors. Twenty-
nine of 30 tumors with NTRK gene fusions confirmed by
DNA-based NGS assays were positive for TRK expression
by immunohistochemistry, and 47 of 48 tumors lacking an
identified NTRK gene fusion by NGS were negative for
TRK expression. The sensitivity and specificity for pan-
TRK immunohistochemistry in this study in relation to the
detection of NTRK gene fusions was therefore 97 and 98%,
respectively. Although further development and broader test-
ing of this approach across multiple tumor types is clearly
required, these studies suggest that a strategy of routine
screening for TRK fusion proteins in common cancers using
immunohistochemistry might be feasible.
5 Resistance Mutations and Solutions
It is now well established that long-term treatment with TKIs
leads to acquired resistance to such agents, typically arising
through the occurrence of mutations that alter drug binding
[17]. In line with such expectations, acquired resistance mu-
tations have been reported in patients with TRK fusion cancer
who had progressed while receiving the pan-TRK, ALK,
ROS1 multikinase inhibitor, entrectinib [70, 87], or
larotrectinib [7, 64]. This issue was specifically investigated
in the recently published integrated analysis of 55
larotrectinib-treated patients with NGS-confirmedNTRK gene
fusion cancers. At progression, tumor or plasma samples were
obtained from nine patients who had an initial documented
objective response, or stable disease for at least 6 months,
and the NTRK gene involved in the fusion was sequenced.
Samples from all nine patients showed one or more kinase
domain mutations affecting this NTRK gene [7]. Mutations
identified included those in solvent front (seven patients),
gatekeeper (two) and xDFG (two) domains, locations within
the kinase similar to those described for resistance mutations
in other classes of kinase inhibitors.
For several TKIs, the problem of acquired resistance has
been addressed by the subsequent development of next-
generation inhibitors, which are clinically active in the pres-
ence of kinase domain mutations that render early generation
agents ineffective. Exceptionally in this field, one such novel
agent, LOXO-195, has been developed in parallel with the
first agent, larotrectinib. LOXO-195 is a potent selective in-
hibitor of all three TRK tyrosine kinases with IC50 values of
<5 nM. Using in vitro and in vivo model systems, it was
initially demonstrated that this TRK inhibitor was active
against TRK proteins with acquired solvent front and xDFG
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domain mutations. In a subsequent first-in-human, proof of
concept investigation, the first two patients with TRK fusion
cancer who developed acquired resistance mutations while on
larotrectinib were treated with LOXO-195 under FDA-
allowed single-patient protocols. Despite the presence of
TRK solvent front resistance mutations, rapid responses
were seen in both patients [88]. This opens up the possi-
bility of extending the period of disease control for pa-
tients with TRK fusion cancer through sequential TRK
inhibitor therapy. A phase I/II study of LOXO-195 in
patients with previously treated TRK fusion cancer is cur-
rently recruiting (NCT03215511).
6 Regulatory Considerations for TRK Inhibitor
Drug Development
Historically, the FDA has granted marketing approval for nov-
el agents for indications based on specific tumor histologies.
The reason for this is that, until recently, the field has consid-
ered treatments as being histology context dependent. This
was exemplified by the differential response to vemurafenib
in BRAF V600E mutated melanoma versus colorectal cancer
[89]. However, on May 23, 2017, the FDA approved an anti-
cancer treatment for the first time, the PD-1 monoclonal anti-
body pembrolizumab, on the basis of tumors having a partic-
ular molecular characteristic, regardless of, or agnostic of,
tumor site [90]. This approval was based on a combined anal-
ysis of 149 patients with metastatic, microsatellite instability-
high (MSI-H) or mismatch-repair-deficient (dMMR) solid tu-
mors; 90 patients had colorectal cancer, and 59 had 1 of
14 other types of tumor. Responses to pembrolizumab
were seen in 40% of patients overall, with response rates
similar for those with colorectal (36%) and other (46%)
cancers. The accelerated approval granted by the FDA for
the MSI-H/dMMR indication required the sponsor to con-
duct further nonrandomized trials to evaluate activity in
additional patients [90].
The broad antitumor activity observed with TRK inhibitors
in patients with TRK fusion cancer also lends itself to be
considered as a tumor agnostic treatment strategy. Both
entrectinib and larotrectinib received orphan drug designation
under the Orphan Drug Act of 1983, since NTRK gene fusions
are found in less than 1% of all solid tumors and have a
combined US prevalence of <200,000, meeting the definition
of a rare disease or condition. Receiving an orphan drug des-
ignation qualifies the sponsor for certain incentives, such as a
waiver of the prescription drug application user fee, tax credits
for qualified clinical testing, and, upon approval, potential 7-
year marketing exclusivity (orphan drug exclusivity). The de-
velopment of novel therapeutics such as TRK inhibitors has
necessitated rethinking of the definitions of ‘disease’, ‘condi-
tion’ and ‘indication’ under the regulatory framework.
7 Conclusions
NTRK gene fusions occur across a wide range of different
tumor types and have now been clinically validated as action-
able genomic alterations. In certain rare tumors, the preva-
lence of such aberrations is typically very high, while in com-
mon cancers, it is thought to be around 1% of cases. The
highly selective TRK inhibitor larotrectinib has been shown
to be generally well tolerated and highly active in patients with
TRK fusion cancer, regardless of tumor type, patient age, and
fusion type. Several multikinase inhibitors with activity
against TRK proteins are also in clinical development, includ-
ing entrectinib. Given the striking differences in the preva-
lence of NTRK gene fusions between certain rare and other
common tumor types, it is likely that future clinical diagnostic
strategies to identify patients who might benefit from TRK
inhibitor therapy will need to be varied accordingly, and
will most likely include FISH, immunohistochemistry
and NGS assays. The approval of pembrolizumab for
MSI-H tumors has set the precedent for considering tissue
agnostic approval for agents, such as TRK inhibitors,
which demonstrate activity across different tumor types
that carry a common genomic alteration.
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